Of­fer­ing a long-await­ed op­tion for the un­vac­ci­nat­ed, FDA au­tho­rizes As­traZeneca's long-act­ing pre­ven­ta­tive an­ti­body

The FDA au­tho­rized As­traZeneca’s long-act­ing mon­o­clon­al an­ti­body cock­tail to pre­vent Covid-19 in pa­tients who are im­muno­com­prised, pro­vid­ing the first lev­el of ad­di­tion­al pro­tec­tion for peo­ple who may not be ad­e­quate­ly pro­tect­ed by vac­cines.

Al­though it will on­ly be for a small sub­set of the pop­u­la­tion, the EUA marks an­oth­er pan­dem­ic mile­stone. Many peo­ple with con­di­tions or on treat­ments that se­vere­ly weak­en their im­mune sys­tems, such as can­cer or mul­ti­ple scle­ro­sis, have found them­selves left be­hind as much of the the coun­try re­opened last year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER